Literature DB >> 29713102

Major Depressive Disorder Following Dermatomyositis: A Case Linking Depression with Inflammation.

Abhishek Reddy1, Badari Birur1, Richard C Shelton1, Li Li1.   

Abstract

Major depressive disorder (MDD) is one of the most common psychiatric disorders. Recent studies have shown a strong association between MDD and peripheral inflammation, shown by a higher incidence of depression in patients with inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus. Dermatomyositis (DM), an idiopathic inflammatory connective tissue disease that is associated with inflammation, predominantly affects the skin and skeletal muscle. The association between DM and MDD in the context of inflammation has seldom been reported. Here we report a 30- year- old Caucasian female with symptoms of depression dating back to 2 years. These symptoms started after cutaneous manifestations of DM. In the past two years, her DM symptoms have worsened that paralleled an increase of depressive symptoms. Also, during the course of the patient's DM, we tracked elevated inflammatory markers including creatine kinase and aldolase, whereas C-reactive protein, C3, and C4 were in a high normal range which correlated with worsening of depression. Hence, a temporal relationship between the onset of MDD and DM symptoms suggests that inflammation may be a common mechanism linking these two conditions.

Entities:  

Keywords:  autoimmune diseases; dermatomyositis; inflammation; inflammatory markers; major depressive disorder

Mesh:

Year:  2018        PMID: 29713102      PMCID: PMC5875364     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  29 in total

1.  Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis.

Authors:  Chris Dickens; Linda McGowan; David Clark-Carter; Francis Creed
Journal:  Psychosom Med       Date:  2002 Jan-Feb       Impact factor: 4.312

2.  The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery.

Authors:  Johan Dahl; Heidi Ormstad; Hans Christian D Aass; Ulrik Fredrik Malt; Lil Träskman Bendz; Leiv Sandvik; Lena Brundin; Ole A Andreassen
Journal:  Psychoneuroendocrinology       Date:  2014-04-06       Impact factor: 4.905

3.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 4.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

Review 5.  Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.

Authors:  M Bryant Howren; Donald M Lamkin; Jerry Suls
Journal:  Psychosom Med       Date:  2009-02-02       Impact factor: 4.312

6.  Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.

Authors:  M Maes; E Bosmans; R De Jongh; G Kenis; E Vandoolaeghe; H Neels
Journal:  Cytokine       Date:  1997-11       Impact factor: 3.861

7.  Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.

Authors:  M R Kraus; A Schäfer; K Schöttker; C Keicher; B Weissbrich; I Hofbauer; M Scheurlen
Journal:  Gut       Date:  2007-12-13       Impact factor: 23.059

8.  Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?

Authors:  Lucile Capuron; Fiona B Fornwalt; Bettina T Knight; Philip D Harvey; Philip T Ninan; Andrew H Miller
Journal:  J Affect Disord       Date:  2009-03-06       Impact factor: 4.839

9.  Dermatopolymyositis and other connective tissue diseases: a review of 105 cases.

Authors:  K E Tymms; J Webb
Journal:  J Rheumatol       Date:  1985-12       Impact factor: 4.666

10.  A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

Authors:  Charles L Raison; Robin E Rutherford; Bobbi J Woolwine; Chen Shuo; Pamela Schettler; Daniel F Drake; Ebrahim Haroon; Andrew H Miller
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.